American Academy of Periodontology best evidence consensus statement on the use of biologics in clinical practice. Issue 12 (24th October 2022)

• Record Type: Journal Article
• Authors: Avila‐Ortiz, Gustavo; Ambruster, Jeanne; Barootchi, Shayan; Chambrone, Leandro; Chen, Chia‐Yu; Dixon, Douglas R.; Geisinger, Maria L.; Giannobile, William V.; Goss, Katie; Gunsolley, John C.; Heard, Rick H.; Kim, David M.; Mandelaris, George A.; Monje, Alberto; Nevins, Marc L.; Palaiologou‐Gallis, Angela; Rosen, Paul S.; Scheyer, E. Todd; Suarez‐Lopez del Amo, Fernando; Tavelli, Lorenzo; Velasquez, Diego; Wang, Hom‐Lay; Mealey, Brian L.
• Is Part Of: Journal of periodontology. Volume 93:Issue 12(2022)
• Page Start: 1763
• Page End: 1770
• Publication Date: 2022-10-24
• Subjects: alveolar ridge preservation -- biologics -- implant site development -- periodontal plastic surgery -- periodontal regeneration -- periodontal therapy; Periodontics -- Periodicals; 617.632
• DOI: 10.1002/JPER.22-0361
• Languages: English
• ISSNs: 0022-3492

Abstract

Abstract: A biologic is a therapeutic agent with biological activity that is administered to achieve an enhanced regenerative or reparative effect. The use of biologics has progressively become a core component of contemporary periodontal practice. However, some questions remain about their safety, indications, and effectiveness in specific clinical scenarios. Given their availability for routine clinical use and the existing amount of related evidence, the goal of this American Academy of Periodontology (AAP) best evidence consensus (BEC) was to provide a state‐of‐the‐art, evidence‐based perspective on the therapeutic application of autologous blood‐derived products (ABPs), enamel matrix derivative (EMD), recombinant human platelet‐derived growth factor BB (rhPDGF‐BB), and recombinant human bone morphogenetic protein 2 (rhBMP‐2). A panel of experts with extensive knowledge on the science and clinical application of biologics was convened. Three systematic reviews covering the areas of periodontal plastic surgery, treatment of infrabony defects, and alveolar ridge preservation/reconstruction and implant site development were conducted a priori and provided the foundation for the deliberations. The expert panel debated the merits of published data and exchanged experiential information to formulate evidence‐based consensus statements and recommendations for clinical practice and future research. Based on an analysis of the current evidence and expert opinion, the panel concluded that the appropriate use of biologics in periodontal practice is generally safe and provides added benefits to conventional treatment approaches. However, therapeutic benefits and risks range based on the specific biologics used as well as patient‐related local and systemic factors. Given the limited evidence available for some indications (e.g., gingival augmentation therapy, alveolar ridge preservation/reconstruction, and implant site development), future clinical studies that can expand the knowledge base on the clinical use of biologics in periodontal practice are warranted.